vs
Caledonia Mining Corp Plc（CMCL）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Caledonia Mining Corp Plc的季度营收约是REGENXBIO Inc.的1.5倍（$46.9M vs $30.3M），Caledonia Mining Corp Plc净利率更高（7.0% vs -221.3%，领先228.4%），REGENXBIO Inc.同比增速更快（43.0% vs 13.8%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 17.1%）
霍赫希尔德矿业是总部位于秘鲁利马、在英国伦敦设有企业办事处的领先银金矿开采企业，业务覆盖北美、中美及南美地区。公司在伦敦证券交易所上市，是富时250指数成分股，大股东为秘鲁企业家爱德华多·霍赫希尔德。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CMCL vs RGNX — 直观对比
营收规模更大
CMCL
是对方的1.5倍
$30.3M
营收增速更快
RGNX
高出29.2%
13.8%
净利率更高
CMCL
高出228.4%
-221.3%
两年增速更快
RGNX
近两年复合增速
17.1%
损益表 — Q3 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $46.9M | $30.3M |
| 净利润 | $3.3M | $-67.1M |
| 毛利率 | 41.2% | — |
| 营业利润率 | 18.6% | -190.0% |
| 净利率 | 7.0% | -221.3% |
| 营收同比 | 13.8% | 43.0% |
| 净利润同比 | -33.3% | -31.2% |
| 每股收益（稀释后） | $0.13 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMCLRGNX
| Q4 25 | — | $30.3M | ||
| Q3 25 | — | $29.7M | ||
| Q2 25 | — | $21.4M | ||
| Q1 25 | — | $89.0M | ||
| Q4 24 | — | $21.2M | ||
| Q3 24 | $46.9M | $24.2M | ||
| Q2 24 | $50.1M | $22.3M | ||
| Q1 24 | $38.5M | $15.6M |
净利润CMCLRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | — | $-61.9M | ||
| Q2 25 | — | $-70.9M | ||
| Q1 25 | — | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $3.3M | $-59.6M | ||
| Q2 24 | $10.2M | $-53.0M | ||
| Q1 24 | $2.1M | $-63.3M |
毛利率CMCLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | 41.2% | 48.8% | ||
| Q2 24 | 45.8% | 52.5% | ||
| Q1 24 | 35.9% | 72.6% |
营业利润率CMCLRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | — | -176.3% | ||
| Q2 25 | — | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | 18.6% | -256.6% | ||
| Q2 24 | 32.2% | -251.3% | ||
| Q1 24 | 13.8% | -408.8% |
净利率CMCLRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | — | -208.3% | ||
| Q2 25 | — | -331.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 7.0% | -246.3% | ||
| Q2 24 | 20.3% | -237.7% | ||
| Q1 24 | 5.4% | -405.4% |
每股收益（稀释后）CMCLRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | $0.13 | $-1.17 | ||
| Q2 24 | $0.42 | $-1.05 | ||
| Q1 24 | $0.07 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.2M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $231.0M | $102.7M |
| 总资产 | $339.7M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CMCLRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | $7.2M | $255.5M | ||
| Q2 24 | $15.4M | $290.4M | ||
| Q1 24 | $1.8M | $338.7M |
股东权益CMCLRGNX
| Q4 25 | — | $102.7M | ||
| Q3 25 | — | $161.5M | ||
| Q2 25 | — | $213.7M | ||
| Q1 25 | — | $274.2M | ||
| Q4 24 | — | $259.7M | ||
| Q3 24 | $231.0M | $301.4M | ||
| Q2 24 | $231.1M | $348.3M | ||
| Q1 24 | $220.3M | $390.7M |
总资产CMCLRGNX
| Q4 25 | — | $453.0M | ||
| Q3 25 | — | $525.2M | ||
| Q2 25 | — | $581.0M | ||
| Q1 25 | — | $490.9M | ||
| Q4 24 | — | $466.0M | ||
| Q3 24 | $339.7M | $519.1M | ||
| Q2 24 | $338.5M | $569.4M | ||
| Q1 24 | $321.8M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | 1.40× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CMCLRGNX
| Q4 25 | — | $-52.3M | ||
| Q3 25 | — | $-56.0M | ||
| Q2 25 | — | $-49.3M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | $4.6M | $-40.5M | ||
| Q2 24 | $19.1M | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流CMCLRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率CMCLRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度CMCLRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率CMCLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CMCL
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
